secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2024-02-23T23:59:59+00:00
Accession:  0001493152-24-007616
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 3.03, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera closes $8M private placement of convertible preferred shares, warrants for up to $8M more
--------------------------------------------------------------------------------

- $8.0 million raised from Series B-1 Preferred at $1,000/share; warrants for additional $8.0 million upon milestone achievement and shareholder approval.
- Conversion price $0.7074; Series B-1 convertible into up to 9,310,677 common shares; warrants into 11,309,019 shares.
- Net proceeds for working capital and development of additional indications for Ameluz (actinic keratosis).
- Initial conversion of preferred shares into 2,516,785 common shares, increasing total outstanding to 5,089,413 common shares.
- Roth Capital Partners acted as placement agent; Rosalind Advisors led institutional investors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224007616/0001493152-24-007616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224007616/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-007616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer